BioNTech SE - American Depositary Shares (BNTX)
108.81
-0.16 (-0.15%)
NASDAQ · Last Trade: Jun 10th, 10:46 AM EDT
Detailed Quote
Previous Close | 108.97 |
---|---|
Open | 109.96 |
Bid | 108.74 |
Ask | 109.16 |
Day's Range | 108.50 - 110.00 |
52 Week Range | 76.53 - 131.49 |
Volume | 89,136 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,229,129 |
Chart
About BioNTech SE - American Depositary Shares (BNTX)
BioNTech SE is a biotechnology company focused on developing and providing transformative therapies for patients suffering from serious diseases. It is primarily known for its pioneering work in mRNA-based vaccines, particularly in the field of infectious diseases and cancer immunotherapy. By leveraging its proprietary technology platform, BioNTech aims to create personalized and innovative treatments that harness the body’s natural immune response. The company is committed to advancing scientific research and bringing novel therapeutics to market, working collaboratively with partners in the pharmaceutical industry and academic institutions to address unmet medical needs globally. Read More
News & Press Releases
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.
Via Benzinga · June 10, 2025
Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust."
Via Stocktwits · June 10, 2025
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.
Via Investor's Business Daily · June 9, 2025

Via Benzinga · June 5, 2025

Via Benzinga · June 3, 2025

Wall Street Climbs Despite Trade Tensions: Steel Stocks Shine, Apple Impresses
Via Chartmill · June 3, 2025

Bristol Myers Squibb just agreed to shower BioNTech with cash.
Via The Motley Fool · June 2, 2025

BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion.
Via Benzinga · June 2, 2025

BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028.
Via Stocktwits · June 2, 2025

Via Benzinga · June 2, 2025

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.
By Bristol Myers Squibb · Via Business Wire · June 2, 2025

MAINZ, Germany, and PRINCETON, USA, June 2, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.
By BioNTech SE · Via GlobeNewswire · June 2, 2025
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.
Via Benzinga · May 27, 2025
MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology portfolio at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, to be held in Chicago, IL, from May 30 to June 3, 2025. The data highlight continued progress of the Company’s clinical programs consisting of complementary therapeutic modalities, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, including antibody-drug conjugates (“ADCs”).
By BioNTech SE · Via GlobeNewswire · May 27, 2025
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter clinical trial requirements for healthy adults.
Via Benzinga · May 21, 2025
Shares of Vaccine stocks are moving higher on Tuesday after documents from the U.S. Food and Drug Administration revealed that its advisers will meet this week.
Via Benzinga · May 20, 2025
The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness.
Via Investor's Business Daily · May 20, 2025
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.
Via Benzinga · May 19, 2025
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.
Via Benzinga · May 19, 2025
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio?
Via Benzinga · May 11, 2025
Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves.
Via Chartmill · May 7, 2025
BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion.
Via Benzinga · May 5, 2025